Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial
In: American Heart Journal, Jg. 235 (2021-05-01), S. 158-162
Online
unknown
Zugriff:
The WiSE system is a novel, leadless endocardial system that can provide cardiac resynchronization therapy in patients who cannot be treated with a conventional epicardial left ventricular lead. Safety and efficacy were being evaluated in the pivotal, randomized, double-blind SOLVE-CRT Trial (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy.) The trial was initiated in 2018; however, patient enrollment was significantly impacted by the COVID-19 pandemic necessitating a change in design. This article describes the revised trial and the scientific rationale for the specific changes in the protocol.
| Titel: |
Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial
|
|---|---|
| Autor/in / Beteiligte Person: | Lindenfeld, JoAnn ; Peter Paul H.M. Delnoy ; Gold, Michael R. ; Auricchio, Angelo ; Kubo, Spencer H. ; Ullery, Steven ; Rinaldi, Christopher A. ; Singh, Jagmeet P. ; Sanders, Prashanthan ; Mary Norine Walsh |
| Link: | |
| Zeitschrift: | American Heart Journal, Jg. 235 (2021-05-01), S. 158-162 |
| Veröffentlichung: | Elsevier BV, 2021 |
| Medientyp: | unknown |
| ISSN: | 0002-8703 (print) |
| DOI: | 10.1016/j.ahj.2021.02.008 |
| Schlagwort: |
|
| Sonstiges: |
|